Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mechanisms of Exercise Benefit with Intravenous Iron in Chronic Heart Failure (FERRIC HF II)
2012-005592-13Phase 4Completed
- Sponsor
- King's College London
- Start
- Dec 2013
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, single-arm trial of ferric derisomaltose in chronic heart failure (CHF), sponsored by King's College London. Primary endpoint: Change in skeletal muscle oxidative capacity (PCr t1/2). Started Dec 2013; status: completed.
02
Drugs
ferric derisomaltose
03
Conditions
chronic heart failure (CHF)
Beyond the preview
Go deeper on 2012-005592-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-005592-13.